

# Alukon®

montelukast

- 24 H anti-leukotriene effect in a single daily dose
- Can be taken with or without food
- Effectiveness and fast relief from the first day
- Proven bronchodilating and antiinflammatory effects in asthma and allergic rhinitis
- Good tolerability - good for compliance
- Can be used in pregnant women
- Reduction of corticosteroids and beta-2 antagonists: an excellent alternative in asthma
- Very affordable price

*Long-term treatment for asthma, even from level 1 for patients who cannot / do not want to use inhaled corticosteroids or who experience intolerable side effects from inhaled corticosteroids, such as persistent hoarseness and those with associated allergic rhinitis.*

## DAILY DOSE : preferably administered in the evening

6 months to 5 years old	1 4-mg <b>granules in sachet</b>
6 to 14 years old	1 4-mg <b>chewable tablet</b>
above age 15 and adults	1 10-mg tablet to be swallowed

**ALUKON®** should not be used in children below age 6 months.

The therapeutic effect of **ALUKON®** on asthma control parameters appears from the first day. Patients should be advised to continue treatment with **ALUKON®**, even if the asthma is stabilized, as well as during periods of symptom exacerbation.

The response to treatment with montelukast should be assessed after 2 to 4 weeks. The treatment should be discontinued if there is no response.

**Never use montelukast to treat acute asthma attacks.**

**DAFRA PHARMA INTERNATIONAL**  
Head Office – Slachthuisstraat 30/7 – 2300 Turnhout – Belgium

3/IAKONE 2021



**Setting the standard**  
[www.dafrapharma.com](http://www.dafrapharma.com)

# Alukon®

montelukast



## REDUCE THE SYMPTOMS OF ASTHMA AND ALLERGIC RHINITIS



LEUKOTRIENE RECEPTOR ANTAGONIST

GIVE YOUR PATIENTS THE MEANS TO BREATHE  
FREELY AND EASILY

FIGHT SYMPTOMS OF ALLERGIC RHINITIS



Setting the standard

[www.dafrapharma.com](http://www.dafrapharma.com)

# Alukon®

montelukast

80% of asthma patients have allergic rhinitis.

Patients with allergic rhinitis are three times more likely to develop asthma.

Asthma and (allergic) rhinitis:  
two inflammatory conditions  
linked by a common airway and  
a common inflammatory mediator,  
**leukotrienes.**

*Symptoms triggered by leukotrienes:  
major causes of reduced quality of life.*

Asthma	Allergic rhinitis
<ul style="list-style-type: none"><li>• continuous respiratory discomfort</li><li>• constriction (smooth muscle contraction) and oedema in the bronchi - breathing problems</li><li>• inflammation and hypersecretion of mucus in the bronchi</li><li>• cough, wheezing and chest tightness</li></ul>	<ul style="list-style-type: none"><li>• rhinorrhea</li><li>• congestion (immediate and long-term)</li><li>• sneezing</li><li>• itching (nasal)</li></ul>

**Leukotrienes are common mediators of  
upper and lower respiratory diseases.**

**By blocking the leukotriene pathway, ALUKON®  
improves asthma symptoms,  
contributes to the control of asthma  
and improves symptoms of allergic rhinitis.**

**Indications for the different forms** from age 6 months to adults:

- **treating asthma**
- **preventing asthma symptoms** during the day and overnight in patients:
  - who are not adequately controlled with their current treatment and who need an additional treatment
  - who have shown an inability to use the inhaled route to administer corticosteroids
  - who have exercise-induced asthma
- **relieving symptoms of seasonal allergic rhinitis**

## Improve the quality of life of your asthma patients Proven efficacy for asthma symptoms

asthmatic cough - wheezing - chest tightness  
dyspnea - nighttime awakening

28 tablets  
10 mg



14 granules in sachet  
4 mg



28 chewable  
tablets  
5 mg



**ALUKON®** is a medical product dispensed by prescription.  
For the complete SMPC, consult [www.dafrapharma.com](http://www.dafrapharma.com)